Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
Veracyte Inc. ownership filing: The Vanguard Group filed an amendment to its Schedule 13G/A reporting 0 shares beneficially owned and 0% of common stock following an internal realignment.
The filing states certain Vanguard subsidiaries will report separately in reliance on SEC Release No. 34-39538 (January 12, 1998), and that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries. The amendment is signed by Vanguard's Head of Global Fund Administration on 03/27/2026.
VERACYTE, INC. filed an initial insider ownership report for Kevin Richard Haas, who serves as Chief Development and Technology Officer. This Form 3 establishes his status as a reporting officer under SEC rules. The filing does not list any buy, sell, or other share transactions, focusing instead on his reporting obligation as a company insider.
Veracyte, Inc. appointed Dr. Kevin Haas, 40, as Chief Development and Technology Officer, effective March 24, 2026. He previously served as Chief Technology Officer and in senior technology and bioinformatics roles at Myriad Genetics and its women’s health business.
Under his offer letter dated March 13, 2026, Dr. Haas will receive an initial annual base salary of $500,000 and will be eligible for an annual performance-based cash bonus targeted at 55% of eligible annual earnings, with his 2026 bonus prorated based on his start date.
He is also slated to receive a restricted stock unit award with a target value of $1,500,000 vesting over four years and a performance-based restricted stock unit award with a target value of $1,500,000, subject to performance objectives and continued service, all under Veracyte’s 2023 Equity Incentive Plan.
Wygant Jonathan reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that its VP and Chief Accounting Officer, Jonathan Wygant, received an equity award in the form of 10,525 shares of common stock on March 6, 2026. The shares were granted at no cash cost to him as part of compensation.
According to the award terms, these restricted stock units vest 25% on March 2, 2027, then 1/16 of the grant vests each quarter after that date, subject to his continued employment on each vesting date. Following this award, he directly holds 45,434 shares of Veracyte common stock.
McGuire Annie reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that SVP and General Counsel Annie McGuire received two equity grants of common stock on March 6, 2026, both at no cash cost to her. Following these awards, she directly holds 153,912 shares.
The first grant of 32,892 restricted stock units vests 25% on March 2, 2027 and then 1/16 each quarter, subject to her continued employment on each vesting date. The second grant of 26,314 restricted stock units vests in full on the first anniversary of the grant, also contingent on continued employment.
Febbo Phillip G. reported acquisition or exercise transactions in this Form 4 filing.
Veracyte, Inc. reported that Chief Scientific & Med Officer Phillip G. Febbo received equity awards in the form of common stock on March 6, 2026. He was granted 29,603 shares and an additional 6,578 shares, both at no cash cost to him.
According to the footnotes, the first award, structured as restricted stock units, vests 25% on March 2, 2027 and then 1/16 each quarter, subject to continued employment. The second award vests in full on the first anniversary of the grant date, also contingent on his continued employment. Following these grants, he directly owns 153,527 shares of Veracyte common stock.
Leite John reported acquisition or exercise transactions in this Form 4 filing.
Veracyte, Inc. reported an equity compensation grant to Chief Commercial Officer-CLIA John Leite. On March 6, 2026, he received two awards of Common Stock totaling 36,181 and 6,578 shares at $0.00 per share as grants rather than open-market purchases or sales. These awards are structured as restricted stock units that vest over time, including a schedule with 25% vesting on March 2, 2027 and quarterly thereafter, and another grant vesting in full on the first anniversary of the grant date, subject to continued employment. Following these transactions, Leite directly owns 150,339 shares of Veracyte common stock.
Stapley Marc reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that Chief Executive Officer Marc Stapley received a grant of 92,099 shares of common stock on March 6, 2026, in the form of restricted stock units. These RSUs vest 25% on March 2, 2027 and 1/16 each quarter thereafter, subject to his continued employment. Following this award, he directly holds 449,653 shares.
Chambers Rebecca reported acquisition or exercise transactions in this Form 4 filing.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported two equity compensation awards in the form of restricted stock units tied to shares of common stock. She was granted 36,181 units and 13,157 units on March 6, 2026, both at no purchase price.
Following these awards, Chambers directly holds 180,534 shares of Veracyte common stock. One award vests 25% on March 2, 2027, with the remainder vesting in equal quarterly installments, while the other vests in full on the first anniversary of the grant, in each case conditioned on continued employment through the vesting dates.
VERACYTE, INC. Chief Financial Officer Rebecca Chambers reported selling a total of 18,341 shares of common stock in open-market transactions on March 4, 2026. The sales were made under a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2025.
The transactions were executed at weighted average prices of $35.5476 and $36.3288 per share, with sale price ranges disclosed in the footnotes. Following these sales, the reporting person directly owned 131,196 shares of Veracyte common stock.